RU2005115536A - Лечение болезни хантингтона с помощью эпк - Google Patents

Лечение болезни хантингтона с помощью эпк Download PDF

Info

Publication number
RU2005115536A
RU2005115536A RU2005115536/14A RU2005115536A RU2005115536A RU 2005115536 A RU2005115536 A RU 2005115536A RU 2005115536/14 A RU2005115536/14 A RU 2005115536/14A RU 2005115536 A RU2005115536 A RU 2005115536A RU 2005115536 A RU2005115536 A RU 2005115536A
Authority
RU
Russia
Prior art keywords
epa
huntington
disease
individuals
identifying
Prior art date
Application number
RU2005115536/14A
Other languages
English (en)
Other versions
RU2332209C2 (ru
Inventor
Дейвид Фредерик ХОРРОБИН (умер)
Original Assignee
Амарин Ньюросайенс Лимитед (GB)
Амарин Ньюросайенс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амарин Ньюросайенс Лимитед (GB), Амарин Ньюросайенс Лимитед filed Critical Амарин Ньюросайенс Лимитед (GB)
Publication of RU2005115536A publication Critical patent/RU2005115536A/ru
Application granted granted Critical
Publication of RU2332209C2 publication Critical patent/RU2332209C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Claims (5)

1. Способ идентификации пациентов с болезнью Хантингтона или индивидуумов, которые подвержены риску развития болезни Хантингтона, которые будут реагировать на лечение с помощью ЭПК в любой биологически доступной форме, включающий стадию определения числа CAG повторов в гене Хантингтина и идентификацию субъектов с числом повторов, равным 45 или меньше.
2. Способ по п.1, при котором лечение включает введение этил-ЭПК.
3. Способ лечения болезни Хантингтона, включающий стадии идентификации пациентов, имеющих 45 или меньшее число CAG повторов в гене хантингтина, и введение этим пациентам ЭПК в любой биологически доступной форме.
4. Способ предотвращения развития симптомов у индивидуумов, которые подвержены риску развития болезни Хантингтона, включающий стадии идентификации индивидуумов, имеющих 45 или меньшее число CAG повторов в гене хантингтина, и введение этим индивидуумам ЭПК в любой биологически доступной форме.
5. Способ по п.3 или 4, при котором вводимая ЭПК находится в форме этил-ЭПК.
RU2005115536/14A 2002-12-02 2003-11-26 Лечение болезни хантингтона с помощью эпк RU2332209C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0228079.0 2002-12-02
GBGB0228079.0A GB0228079D0 (en) 2002-12-02 2002-12-02 Huntington's Disease

Publications (2)

Publication Number Publication Date
RU2005115536A true RU2005115536A (ru) 2006-01-27
RU2332209C2 RU2332209C2 (ru) 2008-08-27

Family

ID=9948921

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005115536/14A RU2332209C2 (ru) 2002-12-02 2003-11-26 Лечение болезни хантингтона с помощью эпк

Country Status (29)

Country Link
US (2) US20070148643A1 (ru)
EP (1) EP1567667B1 (ru)
JP (1) JP2006507833A (ru)
KR (1) KR20050086895A (ru)
CN (1) CN1717497A (ru)
AT (1) ATE411399T1 (ru)
AU (1) AU2003285519A1 (ru)
BR (1) BR0316969A (ru)
CA (1) CA2506727A1 (ru)
CY (1) CY1108730T1 (ru)
DE (1) DE60324180D1 (ru)
DK (1) DK1567667T3 (ru)
ES (1) ES2315543T3 (ru)
GB (1) GB0228079D0 (ru)
HK (1) HK1081598A1 (ru)
HR (1) HRP20050493A2 (ru)
IS (1) IS7842A (ru)
MX (1) MXPA05005908A (ru)
MY (1) MY138759A (ru)
NO (1) NO20052955L (ru)
NZ (1) NZ539989A (ru)
PL (1) PL376101A1 (ru)
PT (1) PT1567667E (ru)
RU (1) RU2332209C2 (ru)
SI (1) SI1567667T1 (ru)
TW (1) TWI306120B (ru)
UA (1) UA86582C2 (ru)
WO (1) WO2004050913A1 (ru)
ZA (1) ZA200504003B (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005208832A1 (en) * 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
AU2007282224B2 (en) 2006-08-11 2013-08-29 Vico Therapeutics B.V. Methods and means for treating DNA repeat instability associated genetic disorders
AU2008273094B2 (en) 2007-07-12 2013-05-09 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
WO2009008727A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
AU2008317566B2 (en) 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR20140007973A (ko) 2009-02-10 2014-01-20 아마린 파마, 인크. 고중성지방혈증 치료 방법
US20120046342A1 (en) 2009-04-24 2012-02-23 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MY172372A (en) 2009-06-15 2019-11-21 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2516647B1 (en) 2009-12-24 2016-12-14 BioMarin Technologies B.V. Molecule for treating an inflammatory disorder
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
BR112014018427B1 (pt) 2012-01-27 2021-11-03 Biomarin Technologies B.V. Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker
EP2866801A4 (en) 2012-06-29 2016-02-10 Amarin Pharmaceuticals Ie Ltd METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT SUBJECTED TO STATIN TREATMENT
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102296068B1 (ko) 2018-09-24 2021-09-02 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
CA2216057A1 (en) * 1997-09-19 1999-03-19 Ridha Joober Polymorphic cag repeat-containing gene, diagnosis of psychiatric diseases and therapeutic uses thereof
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
WO2001024781A2 (en) * 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulating same

Also Published As

Publication number Publication date
BR0316969A (pt) 2005-10-25
US20090270504A1 (en) 2009-10-29
HRP20050493A2 (en) 2005-10-31
MXPA05005908A (es) 2005-12-12
UA86582C2 (ru) 2009-05-12
HK1081598A1 (en) 2006-05-19
EP1567667B1 (en) 2008-10-15
PT1567667E (pt) 2008-11-04
TWI306120B (en) 2009-02-11
RU2332209C2 (ru) 2008-08-27
CY1108730T1 (el) 2014-04-09
IS7842A (is) 2005-05-12
NO20052955L (no) 2005-06-16
US20070148643A1 (en) 2007-06-28
EP1567667A1 (en) 2005-08-31
KR20050086895A (ko) 2005-08-30
SI1567667T1 (sl) 2009-04-30
CN1717497A (zh) 2006-01-04
ATE411399T1 (de) 2008-10-15
GB0228079D0 (en) 2003-01-08
JP2006507833A (ja) 2006-03-09
DE60324180D1 (de) 2008-11-27
MY138759A (en) 2009-07-31
NZ539989A (en) 2006-11-30
ZA200504003B (en) 2007-01-31
TW200418993A (en) 2004-10-01
AU2003285519A1 (en) 2004-06-23
PL376101A1 (en) 2005-12-12
ES2315543T3 (es) 2009-04-01
CA2506727A1 (en) 2004-06-17
DK1567667T3 (da) 2009-01-12
WO2004050913A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
RU2005115536A (ru) Лечение болезни хантингтона с помощью эпк
White et al. Exercise and multiple sclerosis
Macphee et al. Low sexual desire in women: The effects of marital therapy
Hershkovitz et al. Mobility assessment of hip fracture patients during a post-acute rehabilitation program
RU2003104240A (ru) Способ оценки функционального состояния больных с патологией суставов нижних конечностей в процессе реабилитации
Mehdizadeh Tazangi et al. The Effectiveness of Peer Group-Based Training in Adherence to Treatment of Adults with Diabetic Foot Ulcer
RU2087160C1 (ru) Способ коррекции психической ригидности при психотерапевтическом воздействии
TH77464A (th) โรคฮันทิงตัน
Walach et al. No difference between self-reportedly amalgam sensitives and non-sensitives? Listen carefully to the data
Powell On the question of the mental state of centenarians
RU95108895A (ru) Способ экоэпидемиологического прогнозирования клиники ревматизма
RU2286789C2 (ru) Способ эндоэкологической реабилитации больных ишемической болезнью, стенокардией напряжения третьего функционального класса
Eskandarkolaii et al. The Effect of Spiritual Self-Care Training on the Severity of Insomnia of Diabetic Adolescents
RU2187992C2 (ru) Способ лечения атопического дерматита у детей
Magabo et al. Poster 22: Comparison between the cardiovascular responses of the 6-minute walk test and that of treadmill testing in patients undergoing cardiac rehabilitation1
RU2001116705A (ru) Способ прогнозирования риска развития дистрофических заболеваний позвоночника
Bonner Cutting: Understanding and Overcoming Self-Mutilation
Apgar Sodium content of well water vs. local municipal water.
Busse Background Paper on Research in Gerontology: Medical
Davis et al. Neuropsychological clusters within intelligence levels for learning disabled children
RU96109171A (ru) Способ идентификации тела погибшего
RU98118517A (ru) Способ профилактики и лечения экологически зависимого синдрома поражения крови у детей
Embersits MINDDing our children-is autism treatable? Do you know a child with autism or ADD?
Falliers Prevention of Status Asthmaticus
RU2000121890A (ru) Способ лечения больных бронхиальной астмой

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20101127